On ECHEMI
Home > Drugs > Cerebral infarction
Cerebral infarction
Cerebral infarction (CI) is a general term for ischemic stroke, including cerebral thrombosis, lacunar infarction and cerebral embolism, accounting for about 70% of all strokes. It is a brain lesion caused by cerebral blood supply disorder. Cerebral infarction is caused by the sudden reduction or cessation of blood flow in the local artery supplying the brain tissue, which causes ischemia and hypoxia in the blood supply area of the blood vessel, leading to necrosis and softening of the brain tissue, accompanied by clinical symptoms and signs in the corresponding parts, such as hemiplegia, aphasia and other symptoms of neurological dysfunction. 24 to 48 hours after the onset of cerebral infarction, low-density lesions in the corresponding parts can be seen on brain CT scans, with unclear boundaries and a certain space-occupying effect. Brain MRI examination can detect cerebral infarction at an early stage, which is manifested as low signal of T1 in the lesion area and high signal of T2 on weighted images. MRI can detect smaller infarction lesions.
Related Drugs
Defibrase for injection
Indication: (1) Acute cerebral infarction, including cerebral thrombosis, cerebral embolism, transient ischemic attack (TIA), and prevention of recurrent cerebral infarction. (2) Myocardial infarction, unstable angina pectoris, and prevention of recurrent myocardial infarction. (3) Vascular diseases of the limbs, including femoral artery embolism, thromboangiitis obliterans, and Raynaud's disease. (4) Blood in a hyperviscosity state, hypercoagulable state, and prethrombotic state. (5) Sudden deafness. (6) Pulmonary embolism.
Manufacturer:

Beijing Science Sun Pharmaceutical Co., Ltd.

Defibrase for injection
Indication: 1. Acute cerebral infarction, including cerebral thrombosis, cerebral embolism, transient ischemic attack (TIA), and prevention of recurrent cerebral infarction. 2. Myocardial infarction, unstable angina pectoris, and prevention of recurrent myocardial infarction. 3. Vascular diseases of the limbs, including femoral artery embolism, thromboangiitis obliterans, and Raynaud's disease. 4. Blood in a state of high viscosity, high coagulation, and prethrombotic state. 5. Sudden deafness. 6. Pulmonary embolism.
Manufacturer:

Henan Tianzhi Pharmaceutical Co., Ltd.

Defibrase for injection
Indication: (1) Acute cerebral infarction, including cerebral thrombosis, cerebral embolism, transient ischemic attack (TIA), and prevention of recurrent cerebral infarction. (2) Myocardial infarction, unstable angina pectoris, and prevention of recurrent myocardial infarction. (3) Vascular diseases of the limbs, including femoral artery embolism, thromboangiitis obliterans, and Raynaud's disease. (4) Blood in a hyperviscosity state, hypercoagulable state, and prethrombotic state. (5) Sudden deafness. (6) Pulmonary embolism.
Defibrase for injection
Indication: (1) Acute cerebral infarction, including cerebral thrombosis, cerebral embolism, transient ischemic attack (TIA), and prevention of recurrent cerebral infarction. (2) Myocardial infarction, unstable angina pectoris, and prevention of recurrent myocardial infarction. (3) Vascular diseases of the limbs, including femoral artery embolism, thromboangiitis obliterans, and Raynaud's disease. (4) Blood in a hyperviscosity state, hypercoagulable state, and prethrombotic state. (5) Sudden deafness. (6) Pulmonary embolism.
Edaravone Injection
Indication: Used to improve neurological symptoms, daily living activities and functional disorders caused by acute cerebral infarction.
Manufacturer:

China National Medicines Guorui Pharmaceutical Co., Ltd.

Ozagre
Indication: It is suitable for the treatment of acute thrombotic cerebral infarction and movement disorders associated with cerebral infarction.
Manufacturer:

Merro Pharmaceutical Co., Ltd.

Ozagre
Indication: It is suitable for the treatment of acute thrombotic cerebral infarction and movement disorders associated with cerebral infarction.
Manufacturer:

Merro Pharmaceutical Co., Ltd.

Ozagre
Indication: It is suitable for the treatment of acute thrombotic cerebral infarction and movement disorders associated with cerebral infarction.
Manufacturer:

Reyoung Pharmaceutical Co., Ltd.

Ozagre
Indication: It is suitable for the treatment of acute thrombotic cerebral infarction and movement disorders associated with cerebral infarction.
Manufacturer:

Dandong Yichuang Pharmaceutical Co., Ltd.

Hydroxyethyl starch
Indication: No data yet
Manufacturer:

Mudanjiang Wanwei Pharmaceutical Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.